| Literature DB >> 19030110 |
Cheryl Carling1, Doris Tove Kristoffersen, Jeph Herrin, Shaun Treweek, Andrew D Oxman, Holger Schünemann, Elie A Akl, Victor Montori.
Abstract
BACKGROUND: Different presentations of treatment effects can affect decisions. However, previous studies have not evaluated which presentations best help people make decisions that are consistent with their own values. We undertook a pilot study to compare different methods for doing this. METHODS ANDEntities:
Mesh:
Substances:
Year: 2008 PMID: 19030110 PMCID: PMC2585274 DOI: 10.1371/journal.pone.0003693
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flowchart
Figure 2Textual information presented to participants
Figure 3Visual analogue scales used to elicit participants' values
Figure 4Category rating scales used to elicit participants' values
Weighting used to derive the relative importance scores (RIS)
| Weights | |||
| Relative importance Scores | CHD | Pills | Cost |
| RISEU | |||
| VAS | 0.04/0.06 | 1/0 | 1/0 |
| CRS | 0.04/0.06 | 1/0 | 1/0 |
| RISPCA | |||
| VAS | 0.004 | −0.588 | −0.809 |
| CRS | 0.044 | −0.514 | −0.856 |
| RISLR | |||
| VAS | 0.011 | −0.013 | −0.005 |
| CRS | 0.125 | −0.476 | −0.162 |
| RISONE | |||
| VAS | 1 | −1 | −1 |
| CRS | 1 | −1 | −1 |
VAS = visual analogue scale; CRS = category rating scale; RIS = relative importance score. RISEU weights were based on an approximation of participants' expected utility (EU) for a decision (the expected utility of taking statins minus the expected utility of not taking statins using the probabilities shown in the table).
RISPCA weights were based on principle component analysis (PCA).
RISLR weights were based on logistic regression (LR).
RISONE weights were equal weights (ONE).
For RISEU, the estimate of the expected utility (EU) of taking statins was subtracted from the estimate of the expected utility of not taking statins.
For RISPCA, RISLR, and RISONE the undesirable consequences (Pills and Cost) were subtracted from the desirable consequences (reduced risk of CHD).
The formulae used to calculate the weights used for each of the four approaches to weighting (RISEU, RISPCA, RISLR, and RISONE) can be found in Appendix S1.
Participant characteristics
| RRR n (%) | ARR n (%) | NNT n (%) | ER n (%) | TNT n (%) | WN n (%) | Total n (%) | |
| n | 131 | 120 | 131 | 135 | 121 | 132 | 770 |
|
| 75 (57) | 68 (57) | 72 (55) | 81 (60) | 75 (62) | 77 (58) | 448 (58) |
|
| |||||||
| 18–29 | 7 (5) | 10 (8) | 6 (5) | 10 (7) | 8 (7) | 10 (8) | 51 (7) |
| 30–39 | 16 (12) | 11 (9) | 15 (11) | 16 (12) | 17 (14) | 16 (12) | 91 (12) |
| 40–49 | 35 (27) | 33 (28) | 32 (24) | 43 (32) | 36 (30) | 33 (25) | 212 (28) |
| 50–59 | 45 (34) | 44 (37) | 46 (35) | 40 (30) | 40 (33) | 49 (37) | 264 (34) |
| 60–69 | 21 (16) | 13 (11) | 20 (15) | 19 (14) | 14 (12) | 23 (17) | 110 (14) |
| 70–79 | 7 (5) | 4 (3) | 11 (8) | 6 (4) | 4 (3) | 0 | 32 (4) |
| over 80 | 0 | 5 (4) | 1 (1) | 1 (1) | 2 (2) | 1 (1) | 10 (1) |
|
| |||||||
| 8 years or less | 1 (1) | 0 | 0 | 0 | 1 (1) | 3 (2) | 5 (1) |
| 9–12 years | 15 (11) | 12 (10) | 14 (11) | 10 (7) | 12 (10) | 10 (8) | 73 (9) |
| 13–16 years | 56 (43) | 45 (38) | 54 (41) | 67 (50) | 49 (40) | 59 (45) | 330 (43) |
| 17 years or more | 59 (45) | 63 (53) | 63 (48) | 58 (43) | 59 (49) | 60 (45) | 362 (47) |
|
| |||||||
| Canada | 4 (3) | 9 (8) | 6 (5) | 7 (5) | 4 (3) | 8 (6) | 38 (5) |
| Germany | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) | 2 (0) |
| Norway | 0 | 0 | 0 | 0 | 1 (1) | 2 (2) | 3 (0) |
| USA | 110 (84) | 97 (81) | 113 (86) | 109 (81) | 104 (86) | 111 (84) | 644 (84) |
| other | 16 (12) | 14 (12) | 12 (9) | 19 (14) | 12 (10) | 10 (8) | 83 (11) |
|
| |||||||
| GP or Health professional | 34 (26) | 29 (24) | 31 (24) | 27 (20) | 23 (19) | 33 (25) | 177 (23) |
| Scientist or engineer | 22 (17) | 23 (19) | 20 (15) | 25 (19) | 18 (15) | 22 (17) | 130 (17) |
|
| |||||||
| 0 (low) | 16 (12) | 17 (14) | 15 (11) | 14 (10) | 12 (10) | 11 (8) | 85 (11) |
| 1 | 50 (38) | 33 (28) | 47 (36) | 31 (23) | 35 (29) | 36 (27) | 232 (30) |
| 2 (high) | 65 (50) | 70 (58) | 69 (53) | 90 (67) | 74 (61) | 85 (64) | 453 (59) |
|
| |||||||
| 0 | 3 (2) | 5 (4) | 4 (3) | 6 (4) | 9 (7) | 8 (6) | 35 (5) |
| 1 | 58 (44) | 59 (49) | 59 (45) | 69 (51) | 65 (54) | 61 (46) | 371 (48) |
| 2 | 42 (32) | 35 (29) | 44 (34) | 45 (33) | 31 (26) | 41 (31) | 238 (31) |
| 3 | 10 (8) | 4 (3) | 8 (6) | 5 (4) | 4 (3) | 2 (2) | 33 (4) |
| 4 | 18 (14) | 17 (14) | 16 (12) | 10 (7) | 12 (10) | 20 (15) | 93 (12) |
Figure 5Category rating scale (CRS) elicited values mapped on visual analogue scale (VAS) elicited values
Figure 6Distribution of RIS scores derived from VAS values
C-values for logistic regressions: Four models of calculating RIS for visual analogue scales (VAS) scores and categorical rating scale (CRS) scores*
| RRR | ARR | NNT | ER | TNT | WN | Overall | |
|
| |||||||
| RISEU | 0.731 | 0.650 | 0.655 | 0.543 | 0.646 | 0.622 | 0.649 |
| RISPCA | 0.720 | 0.636 | 0.650 | 0.535 | 0.639 | 0.616 | 0.645 |
| RISLR | 0.751 | 0.709 | 0.652 | 0.576 | 0.627 | 0.611 | 0.656 |
| RISONE | 0.728 | 0.697 | 0.649 | 0.553 | 0.643 | 0.617 | 0.657 |
|
| |||||||
| RISEU | 0.794 | 0.647 | 0.694 | 0.598 | 0.659 | 0.629 | 0.667 |
| RISPCA | 0.772 | 0.635 | 0.685 | 0.582 | 0.662 | 0.621 | 0.660 |
| RISLR | 0.832 | 0.657 | 0.682 | 0.614 | 0.630 | 0.653 | 0.671 |
| RISONE | 0.769 | 0.665 | 0.666 | 0.587 | 0.642 | 0.630 | 0.660 |
A c-statistic of 1.0 indicates perfect accuracy, while a c-statistic of 0.5 indicates a non-discriminatory test. The weights used in the four models are shown in Table 1.
Figure 7Log odds for deciding to start taking statins in relation to relative importance scores
Decision to start taking statins and other responses
| RRR n (%) | ARR n (%) | NNT n (%) | ER n (%) | TNT n (%) | WN n (%) | Total n (%) | |
| n | 131 | 120 | 131 | 135 | 121 | 132 | 770 |
|
| 113 (86) | 75 (63) | 83 (63) | 81 (60) | 84 (69) | 81 (61) | 517 (67) |
|
| |||||||
| Not stated | 0 | (1) | (1) | (2) | (3) | (1) | 8 (1) |
| RRR | (59) | (56) | (49) | (53) | (40) | (48) | 393 (51) |
| ARR | (4) | (3) | (2) | (4) | (3) | (5) | 29 (4) |
| NNT | (3) | (4) | (6) | (4) | (4) | (5) | 34 (4) |
| ER | (12) | (12) | (10) | (19) | (16) | (13) | 104 14) |
| TNT | 0 | (2) | (4) | 0 | (2) | (1) | 11 (1) |
| WN | (22) | (22) | (28) | (18) | (32) | (27) | 191 (25) |
|
| |||||||
| 1 (low) | 0 | 1 (1) | 0 | 1 (1) | 0 | 0 | 2 (0) |
| 2 | 7 (5) | 4 (3) | 4 (3) | 7 (5) | 8 (7) | 6 (5) | 36 (5) |
| 3 | 15 (11) | 16 (13) | 14 (11) | 13 (10) | 18 (15) | 14 (11) | 90 (12) |
| 4 | 44 (34) | 51 (43) | 44 (34) | 53 (39) | 38 (31) | 54 (41) | 284 (36) |
| 5 (high) | 65 (50) | 48 (40) | 69 (53) | 61 (45) | 57 (47) | 58 (44) | 358 (47) |
|
| |||||||
| Low confidence | 30 (23) | 31 (26) | 26 (20) | 35 (26) | 30 (25) | 37 (28) | 189 (25) |
| High confidence | 101 (77) | 89 (74) | 105 (80) | 100 (74) | 91 (75) | 95 (72) | 581 (75) |
|
| |||||||
| 1 (low) | 0 | 0 | 0 | 0 | 2 (2) | 0 | 2 (0) |
| 2 | 4 (3) | 8 (7) | 4 (3) | 6 (4) | 4 (3) | 3 (2) | 29 (4) |
| 3 | 15 (11) | 9 (8) | 16 (12) | 14 (10) | 10 (8) | 9 (7) | 73 (9) |
| 4 | 28 (21) | 33 (28) | 25 (19) | 38 (28) | 34 (28) | 33 (25) | 191 (25) |
| 5 (high) | 84 (64) | 70 (58) | 86 (66) | 77 (57) | 71 (59) | 87 (66) | 475 (62) |